ReviewBritish journal of pharmacology2019
Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.
Review in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multimorbidity and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies.The journal of prevention of Alzheimer's disease · 2025Pooled it
- Early-life adversity in rodents: Experimental design is of the essence.Neurobiology of stress · 2026Article
- Association between chronic pain and frailty among Chinese adults aged ≥ 60 years: a cross-sectional study.Internal and emergency medicine · 2026Article
- Serum Amyloid A-Dependent Inflammasome Activation and Acute Injury in a Mouse Model of Experimental Stroke.International journal of molecular sciences · 2026Article
- Article
- Histaminergic System Activity in the Central Nervous System: The Role in Neurodevelopmental and Neurodegenerative Disorders.International journal of molecular sciences · 2024Review
- Association between neutrophil to high-density lipoprotein cholesterol ratio (NHR) and depression symptoms among the United States adults: a cross-sectional study.Lipids in health and disease · 2024Article
- Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.Pharmacology & therapeutics · 2024Review
- Prevalence of Comorbid Dementia in Late-life Depression and Bipolar Disorder: A Retrospective Inpatient Study.Journal of Alzheimer's disease reports · 2022Article
- Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis.Renal failure · 2021Article
- Creation of a gene expression portrait of depression and its application for identifying potential treatments.Scientific reports · 2021Article
- Total Plasma Homocysteine and Depressive Symptoms in Older Hispanics.Journal of Alzheimer's disease : JAD · 2021Article
- Immune dysregulation in depression: Evidence from genome-wide association.Brain, behavior, & immunity - health · 2020Article
- Incidence and Risk Factors for Dementia in Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Korea.Diabetes & metabolism journal · 2020Article
- Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.British journal of pharmacology · 2019Review
- Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine.British journal of pharmacology · 2019Article
- Linking late life depression and Alzheimer's disease: mechanisms and resilience.Current behavioral neuroscience reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Dysfunctional immune activity is a physiological component of both Alzheimer's disease (AD) and major depressive disorder (MDD). The extent to which altered immune activity influences the development of their respective cognitive symptoms and neuropathologies remains under investigation. It is evident, however, that immune activity affects neuronal function and circuit integrity. In both disorders, alterations are present in similar immune networks and neuroendocrine signalling pathways, immune responses persist in overlapping neuroanatomical locations, and morphological and structural irregularities are noted in similar domains. Epidemiological studies have also linked the two disorders, and their genetic and environmental risk factors intersect along immune-activating pathways and can be synonymous with one another. While each of these disorders individually contains a large degree of heterogeneity, their shared immunological components may link distinct phenotypes within each disorder. This review will therefore highlight the shared immune pathways of AD and MDD, their overlapping neuroanatomical features, and previously applied, as well as novel, approaches to pharmacologically manipulate immune pathways, in each neurological condition. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.